State-Specific MPJE Preparation: Federal Core and Labeled Texas Examples Study Guide

Apply it

A Texas technician enters a prescription, selects stock, and flags possible duplicate therapy. The pharmacist evaluates and resolves the concern and completes required verification before release.

Apply it

A Texas pharmacist disputes a dispensing allegation in a disciplinary notice. The pharmacist can present compliance information at the offered informal conference and pursue the stated hearing opportunity if the matter is not resolved.

Apply it

A Texas pharmacist receives a qualifying examination request. The pharmacist arranges the approved evaluation through the coordinating entity, meets the appointment and release requirements, and ensures timely submission of results rather than substituting an independently chosen assessment.

Apply it

An applicant presents a Texas pharmacist diploma and an old license card. Before assigning pharmacist shifts, the pharmacy confirms current license status and any restrictions rather than treating the educational credential as proof of active practice authority.

Apply it

A Texas pharmacist discovers that the license expired before today's scheduled shift. The pharmacist cannot cover the shift as a pharmacist while planning to submit renewal paperwork afterward, even if the pharmacy would otherwise lack coverage.

Apply it

For a 120-day lapse, first identify the license type. An ordinary renewal lapse requires the unpaid renewal fees plus the twice-renewal fee and required continuing-education reporting. An expired initial 30-day license instead follows the initial-license-fee-plus-one-renewal-fee provision.

Apply it

A licensed pharmacist employed in a DEA-registered community pharmacy fills controlled-substance prescriptions in ordinary professional practice. The pharmacist's lack of a separate individual DEA registration does not, by itself, make that dispensing arrangement unlawful.

Apply it

A pharmacy considers assigning controlled-stock receiving duties to someone with a controlled-substance felony conviction. Calling the job administrative does not resolve the restriction; the pharmacy must address the access prohibition and any applicable DEA waiver.

Apply it

An experienced Texas pharmacist offers to supervise an internship but has never obtained board preceptor certification. Experience alone does not establish preceptor status; the pharmacist must satisfy the training, eligibility, and certification requirements.

Apply it

A Texas pharmacy repeatedly releases prescriptions without the required pharmacist verification because its workflow bypasses that step. The pharmacist-in-charge must address the system and personnel assignments; identifying the technician who handled one prescription does not resolve the ongoing compliance problem.

Apply it

A Texas pharmacist's order prohibits serving as pharmacist-in-charge but allows specified staff practice. The employer may consider an assignment within those terms, but may not appoint the pharmacist as pharmacist-in-charge merely because the license has not been suspended.

Apply it

A Texas intern in a board-approved program performs a delegated pharmacist duty under a certified pharmacist preceptor. The intern cannot then independently supervise technicians merely because the delegated clinical task was permitted.

Apply it

An established pharmacist has 30 approved contact hours, including one hour of Texas pharmacy law, but has not completed the required human-trafficking prevention course. The pharmacist must complete and report that course before renewal; the total hours and law component alone are insufficient.

Apply it

A practitioner has an active DEA registration but lacks jurisdictional authority to prescribe the requested controlled-substance category. The pharmacist cannot treat the federal registration as curing the missing scope of practice authority for that prescription.

Apply it

A hospital resident issues a controlled-substance prescription using the hospital's DEA number and assigned internal code. The pharmacist evaluates whether the resident is authorized under the institutional arrangement rather than rejecting it solely for lacking an individual registration.

Apply it

A clinic employee communicates an authorized oral Schedule III prescription on a practitioner's behalf. The pharmacist identifies the authorized prescriber and verifies the order's requirements rather than treating the employee as independently authorized to prescribe controlled substances.

Apply it

A controlled-substance prescription includes the drug and quantity but lacks patient identification. The pharmacist recognizes a prescription-content problem and resolves it through an authorized process before dispensing rather than relying on the patient's verbal claim alone.

Apply it

A practitioner issues several qualifying Schedule II prescriptions on October 1. Each bears October 1 as its issuance date, while later prescriptions contain appropriate earliest-fill instructions governing when the pharmacy may dispense them to the patient.

Apply it

A practitioner proposes three separate 30-day Schedule II prescriptions. The pharmacist checks valid issuance, earliest-fill instructions, jurisdictional permission, and the other federal conditions rather than treating the total 90-day quantity as sufficient by itself.

Apply it

A practitioner determines that a patient needs immediate Schedule II treatment, explains why available alternatives are inappropriate, and cannot reasonably provide a written prescription before the urgently needed dispensing. Those facts satisfy the three emergency criteria; the pharmacist then verifies the caller as needed, records the order, and limits the quantity to the emergency period.

Apply it

A compliant electronic follow-up arrives after emergency dispensing. The pharmacist annotates that electronic record with the original authorization and oral-order date. If paper follow-up arrives instead, the pharmacist checks its required notation and attaches it to the written oral-order record.

Apply it

A clinic asks the pharmacy to fill a controlled-substance prescription under one patient's name so staff can use the medication for several future patients. The pharmacist identifies office-stock acquisition rather than legitimate dispensing for the named patient.

Apply it

A practitioner administers a Schedule II medication during treatment, while a separate community pharmacy is asked to provide take-home medication. The pharmacist evaluates the pharmacy transaction under its prescription requirements rather than borrowing the practitioner's direct-administration exception.

Apply it

A trained Texas pharmacist plans an adult influenza clinic at a site listed in the physician protocol, with required supervision and no other provider immediately available and tasked to vaccinate. If the written protocol does not authorize that location, the service cannot proceed there under this pathway until that condition is satisfied.

Apply it

A Medicaid beneficiary presents a new prescription. The pharmacist offers a discussion and, if accepted, selects significant information based on the patient's therapy and situation rather than assuming that handing over a printed leaflet completes the counseling process.

Apply it

A patient understands the medication's purpose but is confused about administration timing and storage. The pharmacist concentrates on those instructions, checks understanding, and adds other significant precautions instead of repeating only the medication's name and strength.

Apply it

A Medicaid beneficiary declines an offered discussion. The pharmacist follows the applicable refusal-documentation process and still resolves a significant interaction identified during prospective review before deciding whether the medication may be dispensed to that patient.

Apply it

A mail-order pharmacy serving Medicaid beneficiaries in other calling areas provides the offer and toll-free long-distance pharmacist access. A local delivery pharmacy evaluates the specified local-service exception rather than assuming delivery alone triggers a universal toll-free requirement.

Apply it

A treating physician asks the pharmacist about a patient's current medications to evaluate an interaction. The pharmacist identifies the request as a treatment disclosure rather than automatically delaying communication until the patient signs a separate HIPAA authorization.

Apply it

A pharmacist sends medication information to a treating specialist evaluating a suspected interaction. The pharmacist recognizes the provider-treatment exception rather than withholding clinically relevant information solely because it exceeds a routine minimum-necessary disclosure template used for other purposes.

Apply it

A pharmacy employee can open a neighbor's profile but has no work-related reason to do so. The pharmacy evaluates the access against job responsibilities and permitted uses rather than assuming the employee's login makes the browsing appropriate.

Apply it

A billing contractor needs information to resolve a specific prescription claim. The pharmacy follows its minimum-necessary process to provide appropriate claim information rather than routinely sending the patient's complete medication and clinical history for every billing inquiry.

Apply it

A patient-returned bottle does not qualify merely because it looks sealed. By contrast, an eligible noncontrolled unit-dose product retained in a qualifying facility, with intact packaging, adequate remaining dating, no exclusion, pharmacist integrity review, return inventory, and required credit may be restocked under this pathway.

Apply it

A pharmacy receives a lot-specific recall notice at 10 a.m. Monday. Affected stock must be removed within 24 hours and quarantined; action should begin promptly. A container of that drug lacking its lot number is included. Separately, unexpired stock exposed to potentially deteriorating smoke during a fire cannot be dispensed merely because its appearance remains normal.

Apply it

A prescription has complete identifiers, but the pharmacist learns that the named patient is not receiving treatment from the purported prescriber. The pharmacist investigates and resolves the legitimacy concern rather than dispensing solely because the form appears complete.

Apply it

A patient asks to move an unfilled electronic Schedule II prescription to another retail pharmacy. The pharmacists assess applicable law and use the authorized electronic transfer process rather than printing, faxing, or verbally recreating the prescription.

Apply it

A patient wants remaining Schedule IV refills transferred after an earlier refill transfer. The pharmacist determines whether the pharmacies share a qualifying real-time database instead of assuming either unlimited transfers or an absolute prohibition in every arrangement.

Apply it

Before dispensing an outpatient opioid prescription in Texas, the responsible pharmacist reviews the PMP. If the system is inaccessible, the pharmacist documents the good-faith access effort supporting that exception. If the report instead shows overlap, the pharmacist investigates whether prior therapy was discontinued.

Apply it

A Medicaid prescription triggers a serious interaction concern. The pharmacist reviews the patient's actual regimen and takes appropriate resolution steps before dispensing rather than clearing the alert solely because the system permits an override on that screen.

Apply it

A Schedule IV prescription has authorized refills remaining, but more than six months have elapsed since issuance. The pharmacist cannot use those remaining refills under the federal rule and needs appropriate new prescribing authorization for further dispensing.

Apply it

A pharmacy partially fills a Schedule II prescription because stock is insufficient. Its next shipment will arrive after the 72-hour window. The pharmacist notifies the prescriber and does not treat the original shortage partial fill as open indefinitely.

Apply it

An emergency oral prescription is issued Monday morning, and the patient requests a first partial fill Tuesday morning. Under the requested-partial-fill pathway, the remaining portion is due within 72 hours of Monday's issuance, not 72 hours after Tuesday's dispensing. The pharmacist records the request date and each dispensing.

Apply it

A pharmacist receives a Schedule II prescription for a documented terminally ill patient and uses the applicable partial-fill pathway. Each dispensing is recorded, cumulative quantity is tracked, and the prescription's 60-day validity is not mistaken for refill authorization.

Apply it

A Schedule IV prescription first filled October 1 is refilled October 20. Its label must include October 1 as the date of initial filling under §1306.24; displaying only October 20 does not supply that information. The take-home container also requires the §290.5 transfer warning.

Apply it

A patient requests an easy-open container for one prescription because of hand limitations. The pharmacy honors and records the request appropriately without automatically treating it as a standing request for every future prescription filled for that patient.

Apply it

A patient reports replacing a safety cap loosely because it is difficult to close. The pharmacist discusses correct use and suitable packaging options rather than assuming that the presence of a safety-cap design guarantees protection during use at home.

Apply it

A purchaser has already bought 2.4 grams of pseudoephedrine base today and requests another 1.8 grams. The total would be 4.2 grams, exceeding the federal daily limit; only 1.2 grams remains under that quantity limit.

Apply it

A pharmacy orders Schedule II stock from its supplier. It uses the required Form 222 or digitally signed electronic ordering process rather than assuming the supplier's ordinary invoice alone satisfies the federal ordering requirement for that distribution.

Apply it

A central-fill pharmacy sends a completed patient-specific Schedule II prescription to the originating retail pharmacy for final dispensing. The pharmacist identifies the central-fill delivery exception rather than treating the shipment as an ordinary acquisition of retail stock.

Apply it

A newly operating registered pharmacy has no controlled stock on its first day. It documents an initial inventory showing zero controlled substances rather than waiting until the first shipment and treating that invoice as the initial inventory record.

Apply it

A pharmacy maintains daily electronic controlled-stock balances. It still schedules and documents the required federal inventory within the two-year interval, while separately checking whether its jurisdiction requires more frequent counts or additional inventory events for the pharmacy.

Apply it

An opened Schedule III bottle contains approximately 1,100 tablets during inventory. Because it holds more than 1,000 tablets, the pharmacy must obtain an exact count rather than relying on the estimation generally permitted for smaller opened Schedule III–V quantities.

Apply it

A pharmacy discovers a confirmed controlled-substance theft. It sends the required written DEA notification within one business day and completes the electronic Form 106 within 45 calendar days, while continuing reconciliation and any other applicable reporting processes.

Apply it

A pharmacy identifies repeated unexplained shortages of a high-diversion-risk controlled substance. Even if each count is small, the pharmacist evaluates the pattern and access circumstances rather than dismissing the losses solely because no single shortage is large.

Apply it

A Texas sterile-compounding pharmacy proposes storing hazardous stock with ordinary inventory and using protective apparel only during mixing. Both choices fail the rule: separate protective storage is required, and personnel protection extends to receiving, inventory, and disposal.

Apply it

A Texas pharmacy's reinspection finds that previously cited violations remain unresolved. The agent may recommend action against the licensee instead of issuing another warning and extending the same corrective deadline.

Apply it

A Texas patient consents to an immediate-release capsule-to-tablet change that supplies the identical active-ingredient dose and preserves desired outcomes. Those facts can satisfy the dosage-form pathway. A proposed time-release replacement fails that pathway, and a different therapeutic agent requires prior prescriber approval.

Apply it

A traditional pharmacy proposes making a large batch for unspecified future clinic patients. The pharmacist examines whether the plan meets section 503A's patient-specific and limited anticipatory-compounding conditions rather than assuming every pharmacy-made preparation qualifies for the statutory exemptions.

Apply it

A clinic considers purchasing office-use compounded sterile preparations from an outsourcing facility. It evaluates the facility's section 503B status and applicable conditions rather than assuming that patient-specific section 503A rules or FDA approval automatically describe those preparations.

Apply it

A Texas Class A pharmacy hires an experienced sterile-compounding pharmacist and buys equipment but has not received the required inspection or Class A-S license. It cannot begin sterile compounding on those facts; individual expertise and equipment do not supply the required facility authorization.